{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Only patients who have received at least 2 cycles of therapy are eligible for response assessment. The proportion of patients with PHR two months post-treatment will be estimated, with a 95% exact binomial confidence interval. Partial response is defined as the reduction of the difference between involved and uninvolved free light chains (dFLC) of ≥ 50% OR a reduction of ≥ 50% of the M-protein if M-spike is ≥ 0.5 g/dL.","groups":[{"description":"Subjects with AL will receive Bendamustine and Dexamethasone\n\nBendamustine: Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:\n\n* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle\n* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle\n\nAvailable to qualifying subjects is the option to dose escalate to dose level (+)1:\n\n* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)\n* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)\n\nDexamethasone: 40 mg orally on days 1, 8, 15, 22 of each cycle","id":"OG000","title":"Treatment Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Partial Hematologic Response (PHR) Rate","type":"PRIMARY","unitOfMeasure":"Participants"}